Table 2.

Prognostic antibody responses for patients at baseline (before study treatment). Univariate Cox regression has an antigen as a variable and relapse free survival (RFS) and Overall survival (OS) as endpoint, respectively. Multivariate Cox regressions are adjusted to gender, Breslow thickness, ulceration, confirmation of lymph node-negative involvement and treatment arm.

	RFS				DMFS				OS
	univariate		multivariate		univariate		multivariate		univariate		multivariate
Antibodies	HR (95% CI)	p	HR (95% CI)	p	HR (95% CI)	p	HR (95% CI)	p	HR (95% CI)	p	HR (95% CI)	p
GM2	1.55 (1.12 2.15)	0.008	1.40 (1.01 1.94)	0.04	1.49 (1.01 2.19)	0.04	1.26 (0.85 1.87)	0.24	1.43 (0.93 2.20)	0.11	1.21 (0.78 1.87)	0.40
MIA	1.53 (1.13 2.08)	0.006	1.23 (0.90 1.68)	0.19	1.55 (1.08 2.23)	0.02	1.25 (0.87 1.80)	0.24	1.63 (1.10 2.42)	0.01	1.32 (0.88 1.96)	0.18
RhodE2	1.31 (1.03 1.66)	0.02	1.26 (0.99 1.59)	0.06	1.40 (1.06 1.85)	0.02	1.37 (1.03 1.82)	0.03	1.48 (1.08 2.01)	0.01	1.43 (1.05–1.96)	0.02
MPHOSPH6	1.34 (1.03 1.74)	0.03	1.24 (0.95 1.61)	0.12	1.10 (0.79 1.53)	0.58	0.99 (0.71 1.38)	0.95	1.04 (0.72 1.51)	0.82	0.94 (0.64 1.36)	0.73
SSX2	1.26 (0.97 1.64)	0.08	1.42 (1.09 1.85)	0.01	1.20 (0.88 1.65)	0.25	1.31 (0.95 1.80)	0.10	1.06 (0.74 1.52)	0.76	1.13 (0.79–1.63)	0.50
CyclinB1	0.84 (0.65 1.09)	0.19	0.83 (0.64 1.08)	0.17	0.79 (0.58 1.07)	0.13	0.77 (0.57 1.06)	0.11	0.69 (0.48 0.98)	0.04	0.67 (0.47 0.95)	0.03
SCYE1v1	0.99 (0.77 1.28)	0.96	0.87 (0.67 1.13)	0.30	0.91 (0.67 1.24)	0.55	0.80 (0.58 1.09)	0.16	0.72 (0.50 1.05)	0.08	0.63 (0.44–0.92)	0.02